FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208461146> ?p ?o ?g. }

• W3208461146 endingPage "527" @default.
• W3208461146 startingPage "521" @default.
• W3208461146 abstract "Secondary myelodysplastic syndromes and acute myeloid leukemia (sMDS/AML) are rare in children and adolescents and have a dismal prognosis. The mainstay therapy is hematopoietic cell transplantation (HCT), but there has been no innovation in cytoreductive regimens. CP X-351, a fixed 5:1 molar ratio of liposomal cytarabine to daunorubicin, has shown favorable safety and efficacy in elderly individuals with secondary AML and children with relapsed de novo AML. We report the outcomes of 7 young patients (6 with newly diagnosed sMDS/AML and 1 with primary MDS/AML) uniformly treated with CP X-351. Five patients had previously received chemotherapy for osteosarcoma, Ewing sarcoma, neuroblastoma, or T-cell acute lymphoblastic leukemia; 1 had predisposing genomic instability disorder (Cornelia de Lange syndrome) and 1 had MDS-related AML and multiorgan failure. The median age at diagnosis of myeloid malignancy was 17 years (range, 13-23 years). Patients received 1 to 3 cycles of CP X-351 (cytarabine 100 mg/m2 plus daunorubicin 44 mg/m2) on days 1, 3, and 5, resulting in complete morphologic remission without overt toxicity or treatment-related mortality. This approach allowed for adding an FLT3 inhibitor as individualized therapy in 1 patient. Six patients were alive and leukemia-free at 0.5 to 3.3 years after HCT. One patient died as a result of disease progression before HCT. To summarize, CP X-351 is an effective and well-tolerated regimen for cytoreduction in pediatric sMDS/AML that warrants prospective studies." @default.
• W3208461146 created "2021-11-08" @default.
• W3208461146 creator A5009930475 @default.
• W3208461146 creator A5015660850 @default.
• W3208461146 creator A5019842450 @default.
• W3208461146 creator A5023870317 @default.
• W3208461146 creator A5025442855 @default.
• W3208461146 creator A5034893220 @default.
• W3208461146 creator A5046612625 @default.
• W3208461146 creator A5055002089 @default.
• W3208461146 creator A5057345714 @default.
• W3208461146 creator A5064327797 @default.
• W3208461146 creator A5066681200 @default.
• W3208461146 creator A5073492643 @default.
• W3208461146 creator A5079239953 @default.
• W3208461146 creator A5086250633 @default.
• W3208461146 creator A5090398355 @default.
• W3208461146 date "2022-01-18" @default.
• W3208461146 modified "2023-09-30" @default.
• W3208461146 title "CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies" @default.
• W3208461146 cites W1260394250 @default.
• W3208461146 cites W1568498224 @default.
• W3208461146 cites W1921476678 @default.
• W3208461146 cites W1963690117 @default.
• W3208461146 cites W1996215491 @default.
• W3208461146 cites W2055884944 @default.
• W3208461146 cites W2082440968 @default.
• W3208461146 cites W2111724321 @default.
• W3208461146 cites W2168453865 @default.
• W3208461146 cites W2339658711 @default.
• W3208461146 cites W2412453621 @default.
• W3208461146 cites W2559537906 @default.
• W3208461146 cites W2600557870 @default.
• W3208461146 cites W2774620398 @default.
• W3208461146 cites W2805741086 @default.
• W3208461146 cites W2883399820 @default.
• W3208461146 cites W2891815860 @default.
• W3208461146 cites W2909182124 @default.
• W3208461146 cites W2926906529 @default.
• W3208461146 cites W2943736050 @default.
• W3208461146 cites W2946024019 @default.
• W3208461146 cites W2994845187 @default.
• W3208461146 cites W2997806446 @default.
• W3208461146 cites W3025300208 @default.
• W3208461146 doi "https://doi.org/10.1182/bloodadvances.2021006139" @default.
• W3208461146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34710216" @default.
• W3208461146 hasPublicationYear "2022" @default.
• W3208461146 type Work @default.
• W3208461146 sameAs 3208461146 @default.
• W3208461146 citedByCount "9" @default.
• W3208461146 countsByYear W32084611462022 @default.
• W3208461146 countsByYear W32084611462023 @default.
• W3208461146 crossrefType "journal-article" @default.
• W3208461146 hasAuthorship W3208461146A5009930475 @default.
• W3208461146 hasAuthorship W3208461146A5015660850 @default.
• W3208461146 hasAuthorship W3208461146A5019842450 @default.
• W3208461146 hasAuthorship W3208461146A5023870317 @default.
• W3208461146 hasAuthorship W3208461146A5025442855 @default.
• W3208461146 hasAuthorship W3208461146A5034893220 @default.
• W3208461146 hasAuthorship W3208461146A5046612625 @default.
• W3208461146 hasAuthorship W3208461146A5055002089 @default.
• W3208461146 hasAuthorship W3208461146A5057345714 @default.
• W3208461146 hasAuthorship W3208461146A5064327797 @default.
• W3208461146 hasAuthorship W3208461146A5066681200 @default.
• W3208461146 hasAuthorship W3208461146A5073492643 @default.
• W3208461146 hasAuthorship W3208461146A5079239953 @default.
• W3208461146 hasAuthorship W3208461146A5086250633 @default.
• W3208461146 hasAuthorship W3208461146A5090398355 @default.
• W3208461146 hasBestOaLocation W32084611461 @default.
• W3208461146 hasConcept C126322002 @default.
• W3208461146 hasConcept C141071460 @default.
• W3208461146 hasConcept C143998085 @default.
• W3208461146 hasConcept C187212893 @default.
• W3208461146 hasConcept C2776694085 @default.
• W3208461146 hasConcept C2777408962 @default.
• W3208461146 hasConcept C2778041864 @default.
• W3208461146 hasConcept C2778336483 @default.
• W3208461146 hasConcept C2778461978 @default.
• W3208461146 hasConcept C2778729363 @default.
• W3208461146 hasConcept C2781413609 @default.
• W3208461146 hasConcept C2911091166 @default.
• W3208461146 hasConcept C71924100 @default.
• W3208461146 hasConceptScore W3208461146C126322002 @default.
• W3208461146 hasConceptScore W3208461146C141071460 @default.
• W3208461146 hasConceptScore W3208461146C143998085 @default.
• W3208461146 hasConceptScore W3208461146C187212893 @default.
• W3208461146 hasConceptScore W3208461146C2776694085 @default.
• W3208461146 hasConceptScore W3208461146C2777408962 @default.
• W3208461146 hasConceptScore W3208461146C2778041864 @default.
• W3208461146 hasConceptScore W3208461146C2778336483 @default.
• W3208461146 hasConceptScore W3208461146C2778461978 @default.
• W3208461146 hasConceptScore W3208461146C2778729363 @default.
• W3208461146 hasConceptScore W3208461146C2781413609 @default.
• W3208461146 hasConceptScore W3208461146C2911091166 @default.
• W3208461146 hasConceptScore W3208461146C71924100 @default.
• W3208461146 hasIssue "2" @default.
• W3208461146 hasLocation W32084611461 @default.
• W3208461146 hasLocation W32084611462 @default.

• next